13F Filings History of EQUITY INVESTMENT CORP

Latest 13F report
Q4 2025 - 12 Feb 2026
Value $
$4,953,302,271
Signature - Title
Phillip Lorren - Chief Compliance Officer
Location
Atlanta, GA
Summary
This page shows a list of all the recent 13F filings made by EQUITY INVESTMENT CORP. Form 13F is required to be filed within 45 days of the end of a calendar quarter. EQUITY INVESTMENT CORP reported 72 stock holdings with total value $4,953,302,271 as of Q4 2025. Top holdings included GSK, VZ, WFC, USB, and UPS.

Notify me when EQUITY INVESTMENT CORP files a new 13F portfolio report.

⭐ Subscribe ⭐
Holdings Value
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Filing Time
Q4 2025 72 $4,953,302,271 +$478,973,970 -$367,611,397 +$111,362,573 GSK, VZ, WFC, USB, UPS 13F-HR 11 Feb 2026, 21:14
Q3 2025 64 $4,773,578,774 +$382,517,027 -$201,931,928 +$180,585,099 VZ, GSK, WFC, USB, MDT 13F-HR 04 Nov 2025, 21:40
Q2 2025 62 $4,476,928,895 +$568,788,147 -$626,730,269 -$57,942,122 VZ, GSK, WFC, PYPL, USB 13F-HR 05 Aug 2025, 19:38
Q1 2025 66 $4,472,459,292 +$376,382,439 -$413,567,197 -$37,184,758 SGOV, VZ, T, GSK, TTE 13F-HR 02 May 2025, 13:36
Q4 2024 63 $4,265,826,709 +$370,843,074 -$335,625,800 +$35,217,274 T, WFC, VZ, PYPL, KVUE 13F-HR 04 Feb 2025, 19:21
Q3 2024 65 $4,298,204,571 +$214,533,287 -$173,094,834 +$41,438,453 T, VZ, SGOV, PYPL, KVUE 13F-HR 07 Nov 2024, 11:41
Q2 2024 65 $3,915,263,950 +$212,254,743 -$139,674,100 +$72,580,643 T, VZ, SGOV, WFC, GSK 13F-HR 07 Aug 2024, 19:31
Q1 2024 63 $3,997,610,302 +$471,862,957 -$302,433,529 +$169,429,428 VZ, SGOV, T, WFC, UL 13F-HR 06 May 2024, 21:47
Q4 2023 60 $3,559,968,163 +$187,063,487 -$209,226,257 -$22,162,770 VZ, T, SGOV, WFC, GSK 13F-HR 08 Feb 2024, 17:28
Q3 2023 59 $3,213,062,081 +$243,291,826 -$163,074,291 +$80,217,535 SGOV, T, GSK, VZ, TTE 13F-HR 07 Nov 2023, 20:29
Q2 2023 60 $3,231,633,403 +$327,184,649 -$229,280,342 +$97,904,307 SGOV, VZ, GSK, WFC, T 13F-HR 02 Aug 2023, 18:47
Q1 2023 57 $3,050,777,270 +$205,568,868 -$94,731,640 +$110,837,228 T, VZ, GSK, INGR, META 13F-HR 03 May 2023, 21:34
Q4 2022 56 $2,972,858,862 +$278,817,249 -$215,925,414 +$62,891,835 T, TTE, VZ, INGR, GL 13F-HR 07 Feb 2023, 20:47
Q3 2022 53 $2,607,490,000 +$298,158,730 -$213,060,048 +$85,098,682 T, GL, WFC, TTE, INGR 13F-HR 09 Nov 2022, 14:54
Q2 2022 56 $2,700,653,000 +$309,045,770 -$243,220,324 +$65,825,446 GSK, T, VZ, TTE, INGR 13F-HR 08 Aug 2022, 16:36
Q1 2022 59 $2,929,035,000 +$536,761,255 -$470,416,110 +$66,345,145 T, GSK, VZ, WMB, DLTR 13F-HR 10 May 2022, 15:06
Q4 2021 54 $2,762,578,000 +$232,316,864 -$256,950,852 -$24,633,988 GSK, DLTR, VZ, WFC, GD 13F-HR 07 Feb 2022, 20:14
Q3 2021 53 $2,608,400,000 +$61,652,598 -$91,245,728 -$29,593,130 GSK, VZ, WFC, GD, T 13F-HR 15 Nov 2021, 09:56
Q2 2021 53 $2,655,774,000 +$216,249,462 -$189,541,465 +$26,707,997 GSK, VZ, WFC, WMB, AXP 13F-HR 06 Aug 2021, 11:15
Q1 2021 52 $2,515,127,000 +$199,883,098 -$149,015,525 +$50,867,573 VZ, GSK, HIG, WFC, USB 13F-HR 12 May 2021, 15:12
Q4 2020 51 $2,143,968,000 +$173,984,129 -$275,202,553 -$101,218,424 SCHW, GSK, VZ, HIG, USB 13F-HR 09 Feb 2021, 21:42
Q3 2020 52 $1,964,730,000 +$199,931,814 -$309,001,330 -$109,069,516 UPS, VZ, JNJ, GSK, SCHW 13F-HR 12 Nov 2020, 17:23
Q2 2020 50 $2,012,869,000 +$142,655,051 -$344,998,551 -$202,343,500 VZ, UPS, GSK, TFC, TRV 13F-HR 10 Aug 2020, 09:43
Q1 2020 49 $1,938,193,000 +$333,173,371 -$581,235,939 -$248,062,568 VZ, UPS, JNJ, GSK, TRV 13F-HR 11 May 2020, 12:21
Q4 2019 53 $2,908,669,000 +$241,687,530 -$270,698,393 -$29,010,863 SHV, GSK, USB, UPS, TFC 13F-HR 11 Feb 2020, 17:05
Q3 2019 47 $2,801,208,000 +$200,283,167 -$311,771,300 -$111,488,133 SHV, UPS, GSK, USB, KR 13F-HR 12 Nov 2019, 09:32
Q2 2019 62 $2,864,440,000 +$131,297,367 -$292,952,060 -$161,654,693 SHV, EBAY, USB, GSK, AXP 13F-HR 05 Aug 2019, 12:48
Q1 2019 60 $2,963,137,000 +$246,942,032 -$323,449,627 -$76,507,595 SHV, GSK, UPS, XOM, EBAY 13F-HR 07 May 2019, 16:48
Q4 2018 65 $2,772,932,000 +$292,437,455 -$257,609,458 +$34,827,997 SHV, VZ, GSK, USB, EXC 13F-HR 12 Feb 2019, 19:34
Q3 2018 61 $3,098,887,000 +$234,615,469 -$340,591,832 -$105,976,363 SHV, XOM, GSK, TGT, AXP 13F-HR 05 Nov 2018, 16:49
Q2 2018 56 $3,076,756,000 +$157,588,650 -$145,269,923 +$12,318,727 SHV, EXC, XOM, GSK, AXP 13F-HR 03 Aug 2018, 10:25
Q1 2018 57 $3,014,158,000 +$484,669,770 -$348,570,574 +$136,099,196 SHV, GSK, EXC, XOM, USB 13F-HR 07 May 2018, 12:25
Q4 2017 58 $3,002,199,000 +$103,892,904 -$212,186,704 -$108,293,800 EXC, EBAY, AXP, TGT, WFC 13F-HR 12 Feb 2018, 16:08
Q3 2017 53 $2,898,373,000 +$83,349,220 -$194,092,769 -$110,743,549 EBAY, WMT, EXC, AXP, PNC 13F-HR 09 Nov 2017, 20:22
Q2 2017 46 $2,926,472,000 +$93,949,525 -$299,136,227 -$205,186,702 WMT, EXC, EBAY, MDT, AXP 13F-HR 04 Aug 2017, 12:28
Q1 2017 40 $3,071,150,000 +$242,757,532 -$353,662,081 -$110,904,549 EBAY, EXC, WMT, XOM, GSK 13F-HR 09 May 2017, 16:51
Q4 2016 42 $3,108,541,000 $0 $0 $0 WMT, EXC, PEP, XOM, EBAY 13F-HR 02 Feb 2017, 07:55